We have added a new primary medication to the hepatocellular carcinoma (HCC) indication, atezolizumab + bevacizumab. These two monoclonal antibodies are indicated in combination for the treatment of advanced or unresectable HCC in adults who have not received prior systemic therapy.
This brings the number of our HCC drugs to five and the total number of hepatology drugs on our interaction checker to twenty-seven.
We have uploaded PK factsheets to the Prescribing Resources section for atezolizumab and bevacizumab separately. The Interactions with HCC treatment table is yet to be updated, due to the on-going issues with the View All function on the website.
